Pancreatic Cancer Research

ResearcherUniversidad de GranadaActive in the last 2 years

Consolación Melguizo Alonso

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3990-806X; OpenAlex author ID A5040989666. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 17

  1. Preclinical evidence for cytokine-based immunotherapy in pancreatic cancer treatment: A systematic review. Last author DOI 10.1016/j.ijbiomac.2026.153486↗
  2. Computed Tomography-Based Sarcopenia and Pancreatic Cancer Survival-A Comprehensive Meta-Analysis Exploring the Influence of Definition Criteria, Prevalence, a… Co-author DOI 10.3390/cancers17040607↗
  3. Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review. Last author DOI 10.1002/wnan.2013↗
  4. Prevalence of Sarcopenia Determined by Computed Tomography in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Co-author DOI 10.3390/cancers16193356↗
  5. Fungi-Derived Bioactive Compounds as Potential Therapeutic Agents for Pancreatic Cancer: A Systematic Review. Co-author DOI 10.3390/microorganisms12081527↗
  6. Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer. Co-author DOI 10.2147/ijn.s415631↗
  7. Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review. Co-author DOI 10.3390/metabo13070872↗
  8. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine. Co-author DOI 10.1016/j.biopha.2022.113669↗
  9. Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress. Co-author DOI 10.3390/cancers13092058↗
  10. The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study. Co-author DOI 10.3390/cancers13133169↗
  11. Nanomedicine in Pancreatic Cancer: A New Hope for Treatment. Co-author DOI 10.2174/1389450121666200703195229↗
  12. Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics. Co-author DOI 10.3390/cancers12041002↗
  13. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Co-author DOI 10.20892/j.issn.2095-3941.2019.0252↗
  14. Proteomic biomarkers in body fluids associated with pancreatic cancer. Co-author DOI 10.18632/oncotarget.24654↗
  15. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study. Co-author DOI 10.1177/1087057116671490↗
  16. Current Status of Immunotherapy Treatments for Pancreatic Cancer. Co-author DOI 10.1097/mcg.0000000000000623↗
  17. Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers. Co-author DOI 10.1007/s10620-014-3291-3↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jose Carlos Prados · 17 shared papers, 2014–2026 · strength 2.86
  2. Francisco Quiñonero · 9 shared papers, 2019–2026 · strength 1.77
  3. Raúl Ortíz · 9 shared papers, 2014–2024 · strength 1.37
  4. Cristina Jiménez‐Luna · 9 shared papers, 2014–2023 · strength 1.03
  5. Gloria Perazzoli · 6 shared papers, 2019–2023 · strength 0.91
  6. Antonio Jesús Láinez Ramos‐Bossini · 3 shared papers, 2020–2025 · strength 0.61
  7. Antonio Gámez Martínez · 2 shared papers, 2024–2025 · strength 0.50
  8. Jorge Rodríguez-Criado · 1 shared paper, 2026 · strength 0.39
  9. Octavio Caba · 5 shared papers, 2014–2020 · strength 0.37
  10. Kevin Doello González · 3 shared papers, 2019–2021 · strength 0.35
  11. Patricia Lara · 1 shared paper, 2024 · strength 0.28
  12. Joaquina Martínez-Galán · 2 shared papers, 2018–2020 · strength 0.20
  13. Carolina Torres · 3 shared papers, 2014–2018 · strength 0.19
  14. José Pérez del Palacio · 2 shared papers, 2017–2020 · strength 0.18
  15. Pablo Redruello Guerrero · 1 shared paper, 2020 · strength 0.11
  16. Ariadna Martín-Blázquez · 1 shared paper, 2020 · strength 0.11
  17. Francisca Vicente · 1 shared paper, 2020 · strength 0.11
  18. Sandra Ríos Peces · 1 shared paper, 2017 · strength 0.07
  19. Antonia Aránega · 1 shared paper, 2014 · strength 0.04
  20. Sonia Perales Romero · 1 shared paper, 2014 · strength 0.04
  21. Ana Linares · 1 shared paper, 2014 · strength 0.04
  22. Antonio Irigoyen · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.